Clinical trials: in Russia
Healthy Aging, Biomarkers
RUSS-AGE: Creating of a Biological Age Calculator and Study of Aging Phenotypes in the Russian Population
This is a multi-center, cross-sectional, observational study aimed at developing biological age calculators specifically for the Russian population investigating various aging phenotypes.
- Trial name
- RUSS-AGE (NCT07574359)
- Where
- Russia
- Volunteers
- 3,500 people, healthy volunteers welcome
- Sponsor
- Pirogov Russian National Research Medical University
Obesity, Overweight
Research Study to Investigate How Well Semaglutide Tablets Taken Once Daily Work in People Who Are Overweight or Living With Obesity (OASIS 1)
This study is being conducted to see if semaglutide tablets can be used as a treatment to help people living with overweight or obesity lose weight. This study will look at the change in participants body weight.
- Trial name
- OASIS 1 (NCT05035095)
- Testing
- Oral semaglutide
- Where
- 56 sites in United States, Canada and 7 more
- Volunteers
- 667 people
- Sponsor
- Novo Nordisk A/S
Lymphoblastic Lymphoma, Childhood
International Cooperative Treatment Protocol for Children and Adolescents With Lymphoblastic Lymphoma
Primary objectives: Randomization R1, all patients eligible: To examine, whether the cumulative incidence of relapses with involvement of the CNS (CNS relapse, pCICR) can be decreased by a modified induction therapy including…
- Trial name
- LBL 2018 (NCT04043494)
- Testing
- Cyclophosphamide, Cytarabine, Dexamethasone
- Where
- 228 sites in Austria, Belgium and 19 more
- Volunteers
- 683 people
- Sponsor
- University Hospital Muenster
Multiple Myeloma
Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With Nirogacestat in Participants With RRMM
The primary purpose is to determine the safety and tolerability of belantamab mafodotin in combination with nirogacestat and to establish the recommended Phase 2 dose for combination treatment to explore in the cohort expansion…
- Trial name
- NCT07084896
- Testing
- Belantamab mafodotin, Nirogacestat
- Where
- 29 sites in United States, Australia and 11 more
- Volunteers
- 106 people
- Sponsor
- GlaxoSmithKline
Progressive Multiple Sclerosis
Masitinib in the Treatment of Patients With Primary Progressive or Non-active Secondary Progressive Multiple Sclerosis
To evaluate the efficacy and safety of oral masitinib versus placebo in the treatment of patients with primary progressive or secondary progressive multiple sclerosis without relapse.
- Trial name
- MAXIMS (NCT05441488)
- Testing
- Masitinib (4.5)
- Where
- 37 sites in France, Greece and 6 more
- Volunteers
- 800 people
- Sponsor
- AB Science
Coronary Artery Disease
Aroxxen® Inhalation for Cardioprotection After Elective PCI With Stent Implantation
This is an open-label, randomized, multicenter Phase II clinical study designed to evaluate the cardioprotective effect, to determine the optimal dosages and duration of inhalation, and to assess the clinical safety of the…
- Trial name
- NCT07397351
- Testing
- Aroxxen
- Where
- Russia
- Volunteers
- 180 people
- Sponsor
- Research Institute of Geroprotective Technologies
Myelodysplastic Syndrome (MDS)
Study Of Venetoclax Tablet With Intravenous or Subcutaneous Azacitidine to Assess Change in Disease Activity In Adult Participants With Newly Diagnosed Higher-Risk Myelodysplastic Syndrome
Myelodysplastic Syndrome (MDS) is a group of disorders that gradually affect the ability of a person's bone marrow (semi-liquid tissue present in many bones like backbones) to produce normal blood cells.
- Trial name
- Verona (NCT04401748)
- Testing
- Venetoclax, Azacitidine
- Where
- 220 sites in United States, Australia and 21 more
- Volunteers
- 531 people
- Sponsor
- AbbVie
Carcinoma, Renal Cell
A Study of Belzutifan (MK-6482) in Combination With Lenvatinib Versus Cabozantinib for Treatment of Renal Cell Carcinoma (MK-6482-011)
This study will compare the efficacy and safety of belzutifan + lenvatinib versus cabozantinib in participants with advanced renal cell carcinoma (RCC) with clear cell component after prior therapy.
- Trial name
- NCT04586231
- Testing
- Belzutifan, Lenvatinib, Cabozantinib
- Where
- 184 sites in United States, Argentina and 23 more
- Volunteers
- 747 people
- Sponsor
- Merck Sharp & Dohme LLC
Head and Neck Squamous Cell Carcinoma
A Study of Pembrolizumab (MK-3475) With or Without Lenvatinib (E7080/MK-7902) as First Line (1L) Intervention in a Programmed Cell Death-ligand 1 (PD-L1) Selected Population With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC) (MK-7902-010) (KEYNOTE-010)
This is a study of pembrolizumab (MK-3475) with or without lenvatinib (E7080/MK-7902) as a first line intervention in a PD-L1 selected population with participants with recurrent or metastatic head and neck squamous cell…
- Trial name
- NCT04199104
- Testing
- Lenvatinib, Pembrolizumab
- Where
- 152 sites in United States, Australia and 17 more
- Volunteers
- 511 people
- Sponsor
- Merck Sharp & Dohme LLC
Endometrial Neoplasms
Study of Pembrolizumab (MK-3475) Versus Chemotherapy in Mismatch Repair Deficient (dMMR) Advanced or Recurrent Endometrial Carcinoma (MK-3475-C93/KEYNOTE-C93/GOG-3064/ENGOT-en15)
The purpose of this study is to assess the safety and efficacy of treatment with pembrolizumab (MK-3475) compared to a combination of carboplatin and paclitaxel in women with mismatch repair deficient (dMMR) advanced or recurrent…
- Trial name
- NCT05173987
- Testing
- pembrolizumab, carboplatin, paclitaxel
- Where
- 194 sites in United States, Australia and 25 more
- Volunteers
- 280 people
- Sponsor
- Merck Sharp & Dohme LLC
Cerebrovascular Disorders, Gait Disorders, Neurologic
Application of Device-based Training to Improve Postural Control in Older Adults With CCI
The goal of this clinical trial is to improve comprehensive rehabilitation programs for elderly patients with chronic cerebral ischemia by incorporating training methods with biofeedback for postural control training.
- Conditions
- Cerebrovascular Disorders, Gait Disorders, Neurologic, Accidental Fall, Aged
- Trial name
- NCT07358338
- Testing
- "Huber" (LPG-Systems, France), "C-mill" (Physiomed Elektromedizin AG, Germany), Physical therapy
- Where
- Russia
- Volunteers
- 120 people
- Sponsor
- Litvina Lyubov Dmitrievna
Breast Cancer
Implementation Study to Describe and Compare Retention Rate and Adherence to Adjuvant Therapy With Ribociclib With and Without Usage of Mobile Application in Patients With HR+ HER2-negative Stage II and III Breast Cancer in Real-world Practice
This study is designed to evaluate the effect of using the application on the adherence of patients with luminal HER2- breast cancer (BC) stage II-III to adjuvant therapy with ribociclib in combination with an aromatase inhibitor…
- Trial name
- IMPULSE (NCT06905301)
- Testing
- Ribociclib, Letrozole, Anastrozole
- Where
- 7 sites in Russia
- Volunteers
- 240 people
- Sponsor
- Novartis Pharmaceuticals
Plasma Cell Myeloma
A Study to Investigate the Clinical Benefit of Isatuximab in Combination With Bortezomib, Lenalidomide and Dexamethasone in Adults With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant
Primary Objective: -To demonstrate the benefit of isatuximab in combination with bortezomib, lenalidomide, and dexamethasone in the prolongation of progression free survival (PFS) as compared to bortezomib, lenalidomide, and…
- Trial name
- IMROZ (NCT03319667)
- Testing
- Isatuximab SAR650984, Bortezomib, Lenalidomide
- Where
- 104 sites in United States, Australia and 19 more
- Volunteers
- 475 people
- Sponsor
- Sanofi
Primary Biliary Cirrhosis
Study of Seladelpar in Participants With Primary Biliary Cholangitis (PBC)
An Open Label Long-Term Study to Evaluate the Safety and Tolerability of Seladelpar in Subjects with Primary Biliary Cholangitis (PBC)
- Trial name
- NCT03301506
- Testing
- Seladelpar 5 mg Capsule, Seladelpar 10 mg Capsule
- Where
- 109 sites in United States, Argentina and 23 more
- Volunteers
- 340 people
- Sponsor
- Gilead Sciences
Advanced Solid Tumors, Triple Negative Breast Cancer
Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) in Previously Treated Participants With Select Solid Tumors (MK-7902-005/E7080-G000-224/LEAP-005)
The purpose of this study is to determine the safety and efficacy of combination therapy with pembrolizumab (MK-3475) and lenvatinib (E7080/MK-7902) in participants with triple negative breast cancer (TNBC), ovarian cancer…
- Conditions
- Advanced Solid Tumors, Triple Negative Breast Cancer, Ovarian Cancer, Gastric Cancer
- Trial name
- NCT03797326
- Testing
- Pembrolizumab, Lenvatinib
- Where
- 88 sites in United States, Argentina and 15 more
- Volunteers
- 611 people
- Sponsor
- Merck Sharp & Dohme LLC
Pulmonary Embolism (Diagnosis), Respiratory Failure With Hypoxia
Screening for Pulmonary Embolism Using Single-channel Electrocardiogram
It is a prospective, controlled, single-center, observational, non-randomized study. The study is planned to include at least 500 patients 18 years old and older (300 patients in the training sample and 200 patients in the test…
- Conditions
- Pulmonary Embolism (Diagnosis), Respiratory Failure With Hypoxia, Chronic Obstructive Pulmonary Disease (COPD)
- Trial name
- NCT07412418
- Where
- Russia
- Volunteers
- 500 people, healthy volunteers welcome
- Sponsor
- I.M. Sechenov First Moscow State Medical University
Coronary Artery Disease (CAD) (E.G., Angina, Myocardial Infarction, and Atherosclerotic Heart Disease (ASHD)), Peripheral Artery Disease
REGistry of Long-term AnTithrombotic TherApy-1
To assess the rates of ischemic and hemorrhagic complications of long-term antithrombotic therapy in patients with chronic coronary syndromes
- Trial name
- REGATTA-1 (NCT04347200)
- Testing
- Antiplatelet Drug
- Where
- Russia
- Volunteers
- 2,000 people
- Sponsor
- National Medical Research Center for Cardiology, Ministry of Health of Russian Federation
Atrial Fibrillation
REGistry of Long-term AnTithrombotic TherApy-2
To assess the rates of ischemic and hemorrhagic complications of long-term antithrombotic therapy in patients with atrial fibrillation
- Trial name
- REGATTA-2 (NCT04347187)
- Testing
- Anticoagulants
- Where
- Russia
- Volunteers
- 2,000 people
- Sponsor
- National Medical Research Center for Cardiology, Ministry of Health of Russian Federation
Chronic Obstructive Pulmonary Disease
MultIceNtre Non-intERVentional Study for Efficacy,Safety Evaluation of BREZTRI in Pts With COPD in RussiA
This is a retrospective-prospective, non-interventional, multi-centre study that will be conducted in routine clinical settings in Russia.
- Trial name
- MINERVA (NCT06422676)
- Where
- 14 sites in Russia
- Volunteers
- 200 people
- Sponsor
- AstraZeneca
Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis
A Phase 3 Study of Pacritinib in Patients With Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis
This study (study ID PAC203 North America; PAC303 ex-North America) is evaluating 200 mg BID of pacritinib compared to physician's choice (P/C) therapy in patients with MF and severe thrombocytopenia (platelet count <50,000/μL).
- Conditions
- Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis
- Trial name
- PACIFICA (NCT03165734)
- Testing
- Pacritinib, Physician's Choice medications
- Where
- 207 sites in United States, Australia and 22 more
- Volunteers
- 407 people
- Sponsor
- Swedish Orphan Biovitrum
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.